news article, page-2

Thanks dcheckers. 2014 cannot come soon enough!!!

A few lines that stood out for me:

"Hence, we expect CVac treatment progression-free survival to increase during the rest of the trial."

"We've talked to some potential partners, and they will depend on us to provide a scalable manufacturing solution in addition to clinical data,"

"Mr. Lehman suggests that if overall survival in the CANVAS trial is statistically significant, CVac could be approved on the one trial. He adds that if there is a significant improvement only in progression-free survival, European regulators have indicated CVac would be considered for marketing approval"

"He also points out that the company is likely to pursue serious partnering discussions starting in 2014 after all of the Phase 2b data are in"